Study Evaluating Oral MOA-728 in Subjects on Methadone Therapy

• Status: Withdrawn
• Trial end date: 2007-12-01
• Target enrollment: 0
• Participant gender: All

Summary

To evaluate the effects of single oral doses of MOA-728 compared to a positive control in subjects on methadone therapy.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Bausch Health Americas, Inc.; Valeant Pharmaceuticals International, Inc.
• Treatments: Methadone

Criteria

Inclusion:

1. Healthy men or women, aged 18 to 65 years.

2. History of methadone treatment for at least 1 month, at a dose >=30 and <=140 mg/day.

Exclusion:

1. History or active presence of clinically important medical disease.

2. Allergy to opioids.